Earlier this year, it was announced that Instem was part of the Mutamind industry and academic consortium of 9 beneficiaries, funded by EMA and led by Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)1. Instem is collaborating on this 2-year research project to further investigate the mutagenicity of different classes of N-nitrosamines to distinguish highly potent from less potent carcinogens.
The project is making progress and a number of the deliverables have been recently published,2,3,4 In addition, Dr. Kevin Cross has recorded a presentation describing the project.5
If you would like to discuss this project in more detail, please get in touch with Dr. Kevin Cross (email@example.com).
- The QSAR project protocol (QSAR for Nitrosamines EUPAS 46057) is available at: https://www.encepp.eu/encepp/viewResource.htm?id=48784
- The in vitro project protocol (In Vitro NA Mutagenicity EUPAS 49355) is available at: https://www.encepp.eu/encepp/viewResource.htm?id=49356
- The endogenous formation project protocol (GITox EUPAS 49089) is available at: https://www.encepp.eu/encepp/viewResource.htm?id=49090